Skip to content
Black Friday — 30% OFFFree shipping on orders of £99 or more
  1. Home
  2. Hormonal Health & Growth
  3. CJC-1295 with DAC, 2mg
Hormonal Health

CJC-1295 with DAC, 2mg

CJC-1295 with DAC is a synthetic modified peptide compound studied for its interactions with growth hormone-releasing hormone (GHRH) receptor pathways in experimental models.

Presentation: CJC-1295 with DAC, 2mg.

Select the required strength and pack size.

Illustrative packaging generated with AI.

Presentation
Original price was: £479.50.Current price is: £335.65.

Available on request in the United Kingdom

Ask an advisor
An advisor contacts you and the partner pharmacy checks whether and how it can proceed. A valid prescription, or an assessment through an authorised telemedicine service, may be required.
  • Partner pharmacy
  • Personal assistance
  • Discreet delivery
  • Presentation
    CJC-1295 with DAC, 2mg

Shipping & Delivery

  • Normally dispatched within 24 hours of payment confirmation.
  • USPS Regular Shipping · £11.95 · Approx. 3–5 business days
  • FedEx 2 Days Delivery · £28.99 · Approx. 2 business days
  • FedEx Overnight Delivery · £40.99 · Approx. 1 business day

For laboratory research only.

Not for human or veterinary use.

Composition and product details

Overview

CJC-1295 with DAC is a synthetic modified peptide compound studied for its interactions with growth hormone-releasing hormone (GHRH) receptor pathways in experimental models.

The Drug Affinity Complex (DAC) modification — a maleimidopropionyl-lysine moiety at the C-terminus — is studied for its capacity to reversibly bind albumin in experimental systems, producing extended stability compared to the unmodified CJC-1295 variant.

The compound is designed with a 30-amino acid sequence structure incorporating four amino acid substitutions that confer enhanced protease resistance relative to native GHRH(1-29). Research applications include GHRH receptor pathway studies, growth hormone secretagogue signalling research, and comparative DAC-modified versus unmodified peptide pharmacology.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Properties

Chemical Formula C165H269N47O46
Synonyms CJC1295 With DAC, 446262-90-4
Molar Mass 3647.2 g/mol
CAS Number 446262-90-4
PubChem CID 91971820
Available formats Vial · KIT (10 vials)
Shelf Life 36 months

Research

CJC-1295 with DAC is a synthetic 30-amino acid GHRH analogue studied for selective receptor affinity and extended stability in laboratory research models. The compound incorporates four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that confer enhanced protease resistance relative to native GHRH(1-29), and a Drug Affinity Complex (DAC) modification at the C-terminus studied for its capacity to reversibly bind albumin in experimental systems, producing significantly extended peptide stability relative to the non-DAC CJC-1295 variant. Laboratory research has examined its growth hormone secretagogue signalling properties — including proposed modulation of pituitary GHRH receptor pathways and downstream IGF-1 axis signalling — in cell-based and in vivo experimental models. Comparative research protocols frequently pair CJC-1295 with DAC against the non-DAC variant to characterise the contribution of the albumin-binding modification to receptor engagement duration and downstream signalling profiles. Independently third-party HPLC-tested; COA available per batch.

FAQ

What is the Drug Affinity Complex (DAC) modification and how does it affect CJC-1295’s stability in research models?

The DAC modification in CJC-1295 is a maleimidopropionyl-lysine moiety incorporated at the C-terminus of the peptide sequence, studied for its capacity to reversibly bind cysteine-34 of albumin in experimental systems. This albumin-binding interaction is studied for its role in significantly extending the peptide’s stability in biological research models relative to the non-DAC CJC-1295 variant, making the DAC form a standard research tool in protocols requiring sustained receptor pathway engagement over extended experimental timelines.

How do the four amino acid substitutions in CJC-1295 differ from native GHRH(1-29)?

CJC-1295 incorporates D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27 relative to native GHRH(1-29), substitutions studied for their capacity to confer enhanced resistance to proteolytic degradation while preserving GHRH receptor binding affinity. These modifications are examined in comparative structure-activity research contrasting CJC-1295’s stability and receptor binding profile against native GHRH(1-29) and other GHRH analogues.

What advantages does the 10-vial KIT format provide for extended research programs?

The 10-vial KIT format is particularly useful for longitudinal investigations, repeated-dose studies, multi-arm experimental designs, pharmacokinetic research, and chronic pathway-signaling programs requiring consistent compound availability across multiple study phases.

Individually sealed vials allow compound to remain lyophilized until needed, supporting stability throughout extended research timelines. The use of matched-batch material across all ten vials also helps minimize variability between experimental sessions, making the KIT format well suited to long-duration receptor-signaling and comparative pharmacology studies.

Original price was: £479.50.Current price is: £335.65.